Organon & Co

OGN

Company Profile

  • Business description

    Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

  • Contact

    30 Hudson Street
    Floor 33
    Jersey CityNJ07302
    USA

    T: +1 551 430-6900

    https://www.organon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    10,000

Stocks News & Analysis

stocks

Undervalued ASX founder-led companies

Can this strategy pick the winners?
stocks

AI stocks post big gains in Q3. These are the winners and losers

Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks

12 picks for an income portfolio - Q3 2025 update

Fifteen months in and passive income growth has exceeded my target.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,253.6025.70-0.28%
CAC 407,971.78109.76-1.36%
DAX 4024,378.290.51-0.00%
Dow JONES (US)46,694.9763.31-0.14%
FTSE 1009,479.1412.11-0.13%
HKSE26,957.77183.15-0.67%
NASDAQ22,941.67161.160.71%
Nikkei 22548,027.8183.050.17%
NZX 50 Index13,531.2942.050.31%
S&P 5006,740.2824.490.36%
S&P/ASX 2008,956.8019.10-0.21%
SSE Composite Index3,882.7820.250.52%

Market Movers